How to cite this article: Craig FE, Monaghan SA, Surti U, Swerdlow SH. ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones. Cytometry Part B 2012; 82B: 85–92.
ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones†
Article first published online: 26 OCT 2011
Copyright © 2011 International Clinical Cytometry Society
Cytometry Part B: Clinical Cytometry
Volume 82B, Issue 2, pages 85–92, March 2012
How to Cite
Craig, F. E., Monaghan, S. A., Surti, U. and Swerdlow, S. H. (2012), ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones. Cytometry, 82B: 85–92. doi: 10.1002/cyto.b.20623
- Issue published online: 16 FEB 2012
- Article first published online: 26 OCT 2011
- Accepted manuscript online: 30 AUG 2011 03:18PM EST
- Manuscript Accepted: 24 AUG 2011
- Manuscript Revised: 22 AUG 2011
- Manuscript Received: 2 JUN 2011
- B lymphoblastic leukemia;
- flow cytometry;
Flow cytometric immunophenotyping has an established role in the diagnosis and monitoring of B-lymphoblastic leukemia (B-LL). However, the search continues for an optimal reagent set that can identify leukemic blasts with specificity, reproducibility, and sensitivity, at any point during the course of the disease and in every specimen type.
This study evaluated the diagnostic utility of detecting the intracytoplasmic antigens zeta-associated protein (ZAP-70) and Bcl-2 in the distinction between the leukemic blasts of B-LL and hematogones.
In comparison with hematogones in reference specimens, significantly higher levels of Bcl-2 were identified in 21 of 23 (91%) B-LL. In particular, Bcl-2 expression was consistently higher in leukemic blasts with bright intensity CD10 expression than the equivalent most immature (CD10 bright intensity) hematogones. As previously reported, Bcl-2 expression was lower in B-LL with BCR-ABL1 gene rearrangement, but the fluorescence intensity of this group of specimens was still significantly higher than that seen for hematogones. In contrast, ZAP-70 was expressed at significantly higher levels in only 7 of 23 (30%) B-LL and demonstrated other findings that might limit clinical utility, including differences in the level of ZAP-70 expression during therapy and between blasts in the peripheral blood and bone marrow.
Bcl-2 over-expression provides a useful tool for the distinction between B-LL and hematogones. In contrast, although further optimization of the ZAP-70 assay might increase the sensitivity of detection, over-expression of ZAP-70 was identified in only a minority of B-LL. © 2011 International Clinical Cytometry Society